Table Of Contents
- Nasonex Price Comparison Table
- Nasonex Information
- Nasonex Ingredients and Composition
- How Does Nasonex Work?
- How To Take Nasonex and Nasonex Dosage and Administration
- If you suspect a Nasonex Overdose
- Nasonex Side Effects
- Nasonex Warnings
- Nasonex Clinical Trials and Studies
- Nasonex Pill Identification / ID and Appearance
- Credits for Nasonex Information
Brand names: Nasonex
Nasonex Price Comparison Table
| Product | Qty | Medical Fees & Shipping | Price/ Qty | Price | Click to Order |
|---|---|---|---|---|---|
| Nasonex nasal spray 140 dose | 1 | $10.95 | $40.06ea | $40.06 | Buy from PharmaWebCanada |
Nasonex nasal spray 140 dose| Product | Qty | Medical Fees & Shipping | Price/ Qty | Price | Click to Order |
|---|---|---|---|---|---|
| Nasonex 50mcg Nasal Spray | 1 | $18.00 | $119.00ea | $119.00 | Buy from IntegraRx |
| Nasonex 50mcg Nasal Spray | 2 | $18.00 | $94.50ea | $189.00 | Buy from IntegraRx |
| Product | Qty | Medical Fees & Shipping | Price/ Qty | Price | Click to Order |
|---|---|---|---|---|---|
| Nasonex 50mcg 17gm Nasal Spray | 1 | $15.00 | $131.00ea | $131.00 | Buy from RxPayouts |
| Product | Qty | Medical Fees & Shipping | Price/ Qty | Price | Click to Order |
|---|---|---|---|---|---|
| Nasonex 50mcg 17gm Nasal Sprays | 2 | $15.00 | $100.00ea | $200.00 | Buy from RxPayouts |
| Product | Qty | Medical Fees & Shipping | Price/ Qty | Price | Click to Order |
|---|---|---|---|---|---|
| Nasonex | 1 | $18.00 | $138.00ea | $138.00 | Buy from Billing-md |
| Nasonex | 3 | $18.00 | $90.00ea | $270.00 | Buy from Billing-md |
When buying online you have to be aware of a few things:
- All our pharmacies offer free consultation by licensed Doctors, were required.
- Some Pharmacies offer next Day Shipping or Saturday Shipping. This may cost extra.
- All shipping costs are shown before you place your order
- Private & Confidential Service, Secure Online Order Form.
Nasonex Information
Brand Name: Nasonex
Other Common Names: Rinelon
Nasonex Nasal Spray, 50 µg is indicated for the prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and the treatment of the nasal symptoms of perennial allergic rhinitis, in adults and children 12 years of age and older. In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, initiation of prophylaxis with Nasonex Nasal Spray, 50 µg is recommended 2 to 4 weeks prior to the anticipated start of the pollen season.
Nasonex Ingredients and Composition
Mometasone furoate monohydrate, the active component of Nasonex Nasal Spray, 50 µg, is an anti- inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11b,17-dihydroxy-16a -methylpregna-1,4-diene-3,20-dione 17-(2-furoate) monohydrate, the following empirical formula C27H30C12O6•H2O and a molecular weight of 539.45.
Mometasone furoate monohydrate is a white powder. It is practically insoluble in water; slightly soluble in methanol, ethanol, and isopropanol; soluble in acetone and chloroform; and freely soluble in tetrahydrofuran. Its partition coefficient between octanol and water is greater than 5000.
Nasonex Nasal Spray, 50 µg is a metered-dose, manual pump spray unit containing an aqueous suspension of mometa- sone furoate monohydrate equivalent to 0.05% w/w mometasone furoate calculated on the anhydrous basis; in an aqueous medium containing glycerin, microcrystalline cellulose and carboxymethylcellulose sodium, sodium citrate, 0.25% w/w phenylethyl alcohol, citric acid, benzalkonium chloride, and polysorbate 80. The pH is between 4.3 and 4.9.
After initial priming (10 actuations), each actuation of the pump delivers a metered spray containing 100 mg of suspension containing mometasone furoate monohydrate equivalent to 50 µg of mometasone furoate calculated on the anhydrous basis. Each bottle of Nasonex Nasal Spray, 50 µg provides 120 sprays.
How Does Nasonex Work?
Nasonex Nasal Spray, 50 µg is a corticosteroid demonstrating anti- inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.
Mometasone furoate demonstrated no mineralocorticoid, androgenic, antiandrogenic, or estrogenic activity in preclinical studies. After administration of a single intranasal dose of mometasone furoate to adult male rats, the highest drug levels were seen in the esophagus, trachea, nasal passage, and mouth.
In two clinical Nasonex studies utilizing nasal antigen challenge, Nasonex Nasal Spray, 50 µg decreased some markers of the early- and late- phase allergic response. These observations included decreases (vs placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known.
The effect of Nasonex Nasal Spray, 50 µg on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (eg, eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).
How To Take Nasonex and Nasonex Dosage and Administration
Adults and Children 12 Years of Age and Older
The usual recommended Nasonex dose for prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal symptoms of perennial allergic rhinitis is two sprays (50 µg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 µg).
In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Nasonex Nasal Spray, 50 µg (200 µg/day) is recommended 2 to 4 weeks prior to the anticipated start of the pollen season.
Improvement in nasal symptoms generally occurs within 2 days after the first dose. Maximum benefit is usually achieved within 1 to 2 weeks. Patients should use Nasonex Nasal Spray, 50 µg only once daily at a regular interval.
Prior to initial use of Nasonex Nasal Spray, 50 µg, the pump must be primed by actuating ten times or until a fine spray appears. The pump may be stored unused for up to 1 week without repriming. If unused for more than 1 week, reprime by actuating two times, or until a fine spray appears.
Directions for Use
Illustrated Patient's Instructions for Use accompany each package of Nasonex Nasal Spray, 50 µg.
Shake well before each use.
If you suspect a Nasonex Overdose
There are no data available on the effects of acute or chronic overdosage with Nasonex Nasal Spray, 50 µg. Because of low systemic bioavailability, and an absence of acute drug-related systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation. Intranasal administration of 1600 µg (8 times the recommended dose of Nasonex Nasal Spray, 50 µg) daily for 29 days, to healthy human volunteers, was well tolerated with no increased incidence of adverse events. Single intranasal doses up to 4000 µg have been studied in human volunteers with no adverse effects reported. Single oral doses up to 8000 µg have been studied in human volunteers with no adverse events reported. Chronic overdosage with any corticosteroid may result in signs or symptoms of hypercorticism. Acute overdosage with this dosage form is unlikely since one bottle of Nasonex Nasal Spray, 50 µg contains approximately 8500 µg of mometasone furoate.
Nasonex Side Effects
You may experience the following Nasonex side effects
- Headache
- Viral Infection
- Pharyngitis
- Epistaxis/ Blood-Tinged Mucus
- Coughing
- Upper Respiratory Tract Infection
- Dysmenorrhea
- Musculoskeletal Pain
- Sinusitis
Other adverse events which occurred in less than 5% but greater than or equal to 2% of mometasone-treated patients (regardless of relationship to treatment), and more frequently than in the placebo group included: arthralgia, asthma, bronchitis, chest pain, conjunctivitis, diarrhea, dyspepsia, earache, flu-like symptoms, myalgia, nausea, and rhinitis.
Rare cases of nasal ulcers and nasal and oral candidiasis were also reported in patients treated with Nasonex Nasal Spray, 50 µg, primarily in patients treated for longer than 4 weeks.
As with any medication, you may experience additional Nasonex side effects.
Nasonex Warnings
The replacement of a systemic corticosteroid with a topical corticosteroid, such as Nasonex, can be accompanied by signs of adrenal insufficiency and in addition, some patients may experience symptoms of withdrawal; i.e., joint and/or muscular pain, lassitude, and depression. Careful attention must be given when patients previously treated for prolonged periods with systemic corticosteroids are transferred to topical corticosteroids, with careful monitoring for acute adrenal insufficiency in response to stress. This is particularly important in those patients who have associated asthma or other clinical conditions where too rapid a decrease in systemic corticosteroid dosing may cause a severe exacerbation of their symptoms.
If recommended doses of intranasal corticosteroids such as Naxonesare exceeded or if individuals are particularly sensitive or predisposed by virtue of recent systemic steroid therapy, symptoms of hypercorticism may occur, including very rare cases of menstrual irregularities, acneiform lesions, and cushingoid features. If such changes occur, topical corticosteroids should be discontinued slowly, consistent with accepted procedures for discontinuing oral steroid therapy.
Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in nonimmune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chickenpox develops, treatment with antiviral agents may be considered.
Nasonex Clinical Trials and Studies
The efficacy and safety of Nasonex Nasal Spray, 50 µg in the prophylaxis and treatment of seasonal allergic rhinitis and the treatment of perennial allergic rhinitis have been evaluated in 18 controlled trials, and one uncontrolled clinical trial, in approximately 3000 adults (age 17 to 85) and adolescents (age 12 to 16). This included 1757 males and 1453 females, including a total of 283 adolescents (182 boys and 101 girls) with seasonal allergic or perennial allergic rhinitis, treated with Nasonex Nasal Spray, 50 µg at doses ranging from 50 to 800 µg/day. The majority of patients were treated with 200 µg/day. These trials evaluated the total nasal symptom scores that included stuffiness, rhinorrhea, itching, and sneezing. Patients treated with Nasonex Nasal Spray, 50 µg, 200 µg/day had a significant decrease in total nasal symptom scores compared to placebo-treated patients. No additional benefit was observed for mometasone furoate doses greater than 200 µg/day. A total of 350 patients have been treated with Nasonex Nasal Spray, 50 µg for 1 year or longer.
In patients with seasonal allergic rhinitis, Nasonex Nasal Spray, 50 µg demonstrated improvement in nasal symptoms (vs. placebo) within 2 days after the first dose. Maximum benefit is usually achieved within 1 to 2 weeks after initiation of dosing.
Prophylaxis of seasonal allergic rhinitis for patients 12 years of age and older with Nasonex Nasal Spray, 50 µg, given at a dose of 200 µg/day, was evaluated in two clinical studies in 284 patients. These studies were designed such that patients received 4 weeks of prophylaxis with Nasonex Nasal Spray, 50 µg prior to the anticipated onset of the pollen season, how- ever, some patients received only 2 to 3 weeks of prophylaxis. Patients receiving 2 to 4 weeks of prophylaxis with Nasonex Nasal Spray, 50 µg demonstrated a statistically significantly smaller mean increase in total nasal symptom scores with onset of the pollen season as compared to placebo patients.
Nasonex Pill Identification / ID and Appearance
Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 µg is supplied in a white, high- density, polyethylene bottle fitted with a white metered-dose, manual spray pump, and teal- blue dust cap. It contains 17 g of product formulation, 120 sprays, each delivering 50 µg of mometasone furoate per actuation. Supplied with Patient's Instructions for Use (NDC 0085-1197-01).
Store between 2° and 25° C (36° and 77° F). Protect from light.
When Nasonex Nasal Spray, 50 µg is removed from its cardboard container, prolonged exposure of the product to direct light should be avoided. Brief exposure to light, as with normal use, is acceptable.
Credits for Nasonex Information
Nasonex information on this page is copyright by Drug Information at Pharma-Help.com, reprinted with Permission. All Rights Reserved. Other pages with reprint permission include Nasonex.